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TITLE 23 
Prednisolone-induced diabetes mellitus in the cat: A historical cohort.  24 
Keywords:  25 
Glucocorticoid induced hyperglycaemia, corticosteroid, hyperglycaemia, glucosuria 26 
ABSTRACT 27 
Objectives Prednisolone is a commonly used drug in cats and potential adverse effects include 28 
hyperglycaemia and diabetes mellitus. The aims of this study were to evaluate the frequency 29 
and investigate potential predisposing risk factors for development of prednisolone-induced 30 
diabetes mellitus (PIDM) in cats.  31 
Methods The electronic records of a tertiary referral centre were searched for cats receiving 32 
prednisolone at a starting dose of ≥1.9 mg/kg/day, for >3 weeks and with follow-up data 33 
available for >3 months between January 2007 and July 2019. One hundred and forty-three cats 34 
were included in the study. 35 
Results Of the 143 cats, 14 cats (9.7%) were diagnosed with prednisolone-induced diabetes 36 
mellitus. Twelve out of 14 cats (85.7%) developed diabetes within 3 months of the initiation of 37 
therapy.   38 
Conclusion and relevance Cats requiring high-dose prednisolone therapy should be closely 39 
monitored over the first 3 months of therapy for development of prednisolone-induced diabetes 40 
mellitus.   41 
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Introduction 42 
Diabetes mellitus (DM) is one of the most commonly diagnosed endocrine 43 
diseases in cats. Diabetes mellitus is characterised by clinical signs including 44 
polyuria and polydipsia due to persistent hyperglycaemia and glucosuria as 45 
well as polyphagia and weight loss due to an absolute or relative lack of 46 
insulin1. Most cats develop a disease comparable to type 2 DM in people and it 47 
is thought to develop due to a combination of insulin resistance and beta-cell 48 
dysfunction due to environmental and genetic factors2. Environmental factors 49 
include obesity3 and glucocorticoid administration4. Glucocorticoids are 50 
commonly used drugs in veterinary medicine for treatment of a variety 51 
disorders due to their anti-inflammatory and immune-suppressive properties5. 52 
Although they are widely used, they also cause a range of adverse effects, 53 
including alterations on glucose homeostasis. Glucocorticoid-induced diabetes 54 
mellitus (GIDM) is well recognised in humans6. Dose and duration of therapy 55 
as well as patient body weight, amongst others, have been described as risk 56 
factors for development of GIDM. 57 
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In feline patients, glucocorticoids have been suggested as a predisposing factor 58 
for development of DM4 and experimental studies have shown the diabetogenic 59 
effects of prednisolone, dexamethasone, methylprednisolone and 60 
fluorohydrocortisone in cats7-10. Despite prednisolone being perhaps the most 61 
commonly used glucocorticoid in cats, prednisolone induced diabetes mellitus 62 
(PIDM) is a poorly described entity in clinical practice. The aim of this study 63 
was to determine the prevalence of PIDM in a feline referral-population 64 
receiving prednisolone therapy and to further characterise potential 65 
predisposing factors in the development of PIDM. 66 
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Material and methods 74 
Selection of cases 75 
The study protocol was approved by the Ethics Committee of the Royal 76 
Veterinary College (Royal Veterinary College Ethical Approval Number 77 
URN2017 – 1513). The electronic medical record system of a tertiary referral 78 
institution was searched from January 2007 to July 2019 using following search 79 
terms: cat, feline, prednisolone, pred, steroids, corticosteroids and 80 
glucocorticoids. Identified records were then reviewed in detail and referring 81 
veterinarians were contacted by telephone or email to obtain follow-up 82 
information where necessary. Cats were included for analysis if following 83 
criteria were all met: 84 
1. Initial prednisolone dose was ≥ 1.9 mg/kg/day. 85 
2. Duration of treatment was a minimum of 3 weeks. 86 
3. Follow-up data for at least 3 months after initiation of prednisolone 87 
therapy was available.  88 
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Cats that had received glucocorticoid therapy within 3 weeks of presentation or 89 
were diabetic prior to or at the time of presentation and cats with neoplastic 90 
diseases, including feline hyperadrenocorticism, were excluded.  91 
 92 
Cats were considered to have developed prednisolone-induced diabetes 93 
mellitus if they had typical clinical signs associated with diabetes mellitus (e.g. 94 
polyuria, polydipsia, weight loss and polyphagia) and if they had one of the 95 
following criteria fulfilled  96 
1. Hyperglycaemia (>8.1 mmol/L on more than two occasions) in 97 
conjunction with glucosuria 98 
2. Hyperglycaemia in conjunction with increased fructosamine levels  99 
 100 
Medical records review 101 
The following details were extracted from the medical records in all cats; 102 
signalment (age, sex, body weight and breed), working or final diagnosis and 103 
initial prednisolone dose, duration of prednisolone therapy, frequency of 104 
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administration and development of PIDM. In addition, serum serum alanine 105 
aminotransferase (ALT) and alkaline phosphatase (ALP) activities, serum 106 
cholesterol concentration, urine specific gravity, glucosuria measured by urine 107 
colorimetric dipstick, blood glucose concentration and body condition score 108 
(BCS, scoring from 1 to 9 where 4 and 5 were considered normal) on 109 
presentation were noted when available.  110 
Statistical analysis 111 
Data was compiled in Microsoft Excel and imported into Stata 15 (Stata Corp., 112 
College Station, TX), which was used for all statistical analyses. A p-value of 113 
<0.05 was considered statistically significant. The continuous variables were 114 
assessed graphically and by the Shapiro-Wilks test for normality and are 115 
presented as medians (ranges). The categorical variables are described as 116 
numbers (percentages). Breed was categorised as pure bred or mixed breed for 117 
the statistical analysis. Associations between categorical and continuous 118 
variables were explored by the two-sample t-test and Wilcoxon rank sum test 119 
for normally and non-normally distributed variables, respectively. Associations 120 
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between categorical variables were tested using the χ2 test or the Fisher exact 121 
test. Univariable logistic regression was used to explore the relationship 122 
between prednisolone dose and PIDM development. Kaplan-Meier curves were 123 
used to visualise time to development of diabetes in the PIDM group and cats 124 
were censored if they died or were lost to follow-up. Box plot were used to 125 
visualise prednisolone starting doses between the groups. Multivariable 126 
analysis was not performed due to the lack of statistical power and limited 127 
number of cases. 128 
Results 129 
Signalment and underlying causes 130 
One hundred and forty-three (143) cats fulfilled all inclusion criteria (see figure 131 
1). Of these, 66 (46%) were male and 77 (54%) were female. Breed distribution is 132 
shown in table 1. Fourteen of 143 cats (9.8%) were diagnosed with PIDM. None 133 
of the cats developing PIDM were Burmese.  The median overall age at the time 134 
of presentation was 5.9 years (0.6-18) and no significant difference in age was 135 
found in cats developing PIDM and cats that did not develop PIDM (p = 0.895).  136 
 137 
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Figure 1: Inclusion details of 143 cats in a cohort study of prednisolone-induced diabetes mellitus 155 
 156 
 157 
 158 
 159 
 160 
 161 
Electronic journal 
system search revealed  
1368 cases 
1135 cases excluded 
due to failure to fulfill 
inclusion criteria or 
fulfilling exclusion 
criteria 
233 cases 
143 cases included 
in final analysis 
90 cases excluded due 
to insufficient follow up 
information available. 
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Breed n 
Domestic Short hair 82 
Domestic Long Hair 10 
Persian 8 
Bengal 6 
Maine Coon 6 
British Short Hair 5 
Burmese 5 
British Blue 4 
Siamese 4 
Cross Breed 2 
Russian Blue 3 
Oriental Short Hair 2 
Burmilla 1 
Chantilly- Tiffany 1 
Devon Rex 1 
Korat 1 
Norwegian Forest Cat 1 
Snowshoe 1 
 162 
Table 1. Breed distribution of 143 cats in a cohort study of prednisolone-induced diabetes mellitus 163 
Overall median body weight was 4.0 kg (2.4-7.9) and no significant difference in 164 
body weight between the PIDM group and non-PIDM group was identified (p = 165 
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0.980). BCS was recorded in 100/143 of cases (13/14 of the PIDM group and 166 
87/129 of the non-PIDM group), and the median BCS for both groups was 4/9. 167 
There were no statistical differences in breed, sex distribution or neuter status 168 
between the two groups (p = 0.238, p = 0.385, p = 0.467, respectively; see table 2 169 
for further details). Immune-mediated haemolytic anaemia and inflammatory 170 
bowel disease and dermatological diseases were the three most common 171 
underlying diseases treated with prednisolone (table 3). Seven (50%) of the cats 172 
developing PIDM were treated for immune-mediated haemolytic anaemia, two 173 
cats were treated for IBD and two for dermatological diseases. One cat was 174 
treated for each of the following diseases: pure red cell aplasia, chronic rhinitis 175 
and cholangitis.  176 
 177 
 
 
    
Variables PIDM non-PIDM Overall 
Age in years 7.5 (1.2-13.2) 5.9 (0.6-18.0) 5.9 (0.6-18.0) 
Weight in kg 4.5 (2.2-5.4) 4.0 (2.2-8.1) 4.0 (2.2-8.1) 
  12 
 
BCS (1-9) 4 (2-7) 4 (1-9) 4 (1-9) 
Sex (%) 
   
  Male entire 1 (7.1) 3 (2.3) 4 (2.8) 
  Male neutered 7 (50.0) 55 (42.6) 62 (43.4) 
  Female entire 0 (0.0) 2 (1.6) 2 (1.4) 
  Female neutered 6 (42.9) 69 (53.5) 75 (52.5) 
Continuous variables reported as a median (range) and categorical variables as number (%). 178 
Body condition score = BCS. Prednisolone-induced diabetes mellitus = PIDM.  179 
Table 2. Descriptive features of 143 cats in a cohort study of prednisolone-induced diabetes mellitus. 180 
 181 
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 184 
 185 
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 188 
 189 
  
Diagnosis N 
Immune-mediated haemolytic anaemia 58 
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Inflammatory bowel disease 22 
Dermatological diseases 21 
Feline asthma  12 
Immune-mediated thrombocytopenia 8 
Inflammatory or immune-mediated disease suspected, but not 
confirmed  3 
Hepatitis or cholangiohepatitis 3 
Inflammatory ocular disease 3 
Neurological diseases 1 
Chronic rhinitis 1 
Polyarthropathy 1 
Myelodysplastic syndrome  1 
Red cell aplasia 1 
Idiopathic hypercalcemia 1 
Laryngitis 1 
 190 
Table 3. Details of underlying causes in 143 cats in a cohort study of prednisolone-induced diabetes 191 
mellitus. 192 
 193 
PIDM and hyperglycaemia 194 
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The median prednisolone starting dose for the study population as a whole was 195 
3.0 mg/kg. The PIDM group received higher daily starting doses of 196 
prednisolone than the non-PIDM group (median 3.5 (2.0-4.4) vs 2.9 (1.9-5.0) 197 
mg/kg/day, figure 2), but this was not statistically significant (p = 0.164).  The 198 
median length of prednisolone treatment was 6 months and no statistical 199 
difference was found in duration of prednisolone therapy (p = 0.284) between 200 
the groups. One of the 14 (7%) cats in the PIDM group was administered 201 
prednisolone twice daily, and 23/129 (17%) in the non-PIDM group. Nine of the 202 
14 (65%) cats developing PIDM were started on insulin therapy. 203 
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 204 
Figure 2: Box-plot showing the starting prednisolone dose in the PIDM and non-PIDM groups. 205 
 206 
Twelve of the 14 cats in the PIDM group received the diagnosis within the first 207 
3 months of treatment (figure 3). The remaining two cats were never tapered off 208 
their prednisolone therapy and both developed DM following a prednisolone 209 
dose increase (from 1.0 mg/kg to 1.7mg/kg and from 0.25mg/kg to 2mg/kg 210 
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respectively) after being diagnosed with a relapse of their underlying immune-211 
mediated disease (thrombocytopenia and anaemia) after 108 and 128 weeks 212 
being on prednisolone, respectively.  213 
 214 
Figure 3: Kaplan-Meier curve showing the time to development of prednisolone-induced diabetes mellitus 215 
in weeks. The vertical lines reflect censored cases.  216 
 217 
The assessed clinicopathological values, measured prior to prednisolone 218 
therapy, are summarised in table 5. Neither blood glucose concentration, serum 219 
cholesterol concentration, serum ALP nor ALT activities were associated with 220 
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the development of PIDM (p = 0.180, 0.623, 0.418 and 0.513, respectively). 221 
Urinalysis prior to prednisolone treatment was available in 9/14 cats of the 222 
PIDM group and 72/129 cats of the non-PIDM group. Glucosuria was detected 223 
in 4/9 (44.4%) and 11/72 (15.3%) of the cats, respectively (p = 0.056).  224 
    
 
PIDM non-PIDM Overall 
Variables (units; 
reference 
intervals) Median (range) n Median (range) n 
Median 
(range) n 
Blood glucose 
(mmol/l; 3.4 -
8.1) 8.7 (5.0-14.4) 
1
0 7.1 (2.54-17.0) 56 7.2 (2.5-17.0) 66 
Cholesterol 
(mmol/l; 2.2-6.7) 3.3 (2.3-8.1) 
1
3 3.2 (1.8-14.4) 
10
7 3.3 (1.8-14.4) 
12
0 
ALT (IU/l; 25-
130) 57 (26-570) 
1
3 59 (0-1186) 
10
7 58.5 (0-1186) 
12
0 
ALP (IU/l; 11-58) 23 (1-305) 
1
3 17 (0-352) 
10
6 17 (0-352) 
11
9 
ALT = alanine aminotransferase. ALP = alkaline phosphatase.  225 
Table 4. Biochemical values in 143 cats in a cohort study of prednisolone-induced diabetes mellitus. 226 
 227 
  18 
 
Discussion 228 
The prevalence of PIDM was 9.7% in our study. This is lower than the reported 229 
prevalence of 18.7% in people6, but significantly higher compared to proposed 230 
prevalence of spontaneous feline DM in first opinion practices in the UK, which 231 
has been reported to be 0.42% and 0.43%2,4. As our study population is from a 232 
tertiary referral centre the prevalence noted in our study might not be 233 
representative of the general feline population, but is suggestive of an increased 234 
risk for cats receiving high doses of prednisolone to develop diabetes mellitus. 235 
To the authors’ knowledge, no previous studies have reported the prevalence of 236 
feline PIDM in client owned cats, but feline experimental studies have shown 237 
the diabetogenic effects of prednisolone. Interestingly, two experimental studies 238 
revealed a higher prevalence of hyperglycaemia and glucosuria in laboratory 239 
cats receiving prednisolone than compared to our study; Middleton and 240 
Watson8 showed that three out of six cats (50%) receiving 2mg/kg/day of 241 
prednisolone developed hyperglycaemia after 7 days and it was shown by 242 
Lowe and colleagues9 two out of seven cats (29%) receiving 4.4mg/kg/day 243 
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developed glucosuria (as a marker of hyperglycaemia) after 28 days. The higher 244 
prevalence of hyperglycaemia and glucosuria in these studies likely reflects 245 
both differences in study design and marked differences in monitoring 246 
compared to our study.  247 
GIDM is well described in humans. Factors including dose, duration of 248 
glucocorticoid therapy, cumulative (or absolute) dose, relative potency of the 249 
glucocorticoid, age, weight, known reduced insulin sensitivity and family 250 
history of diabetes have been found to increase the risk of GIDM6. The starting 251 
prednisolone dose was not significantly associated with development of PIDM 252 
in our study, however a trend could be observed with a higher dose range 253 
noted in the PIDM cats (3.5 vs 2.9 mg/kg). This is similar to what has been 254 
shown in people, where high dose prednisolone therapy is more likely to 255 
induce glucose intolerance11. To avoid development of GIDM in people it has 256 
been suggested to start in the lower end of the dose range and to reduce the 257 
administration frequency to once daily or every other day once the underlying 258 
disease is controlled6,12,13. Recently, it has also been shown in dogs that once 259 
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daily administration of prednisolone was associated with less side effects than 260 
twice daily dosing14. Although no clear dose range has been established in cats, 261 
it is likely that cats would benefit from a low-end starting dose and probably 262 
also reduction in administration frequency to reduce the risk of side effects. The 263 
majority of the cats in our study developed PIDM within 3 months of initiation 264 
of therapy, which further supports a dose-dependent relationship.  265 
Another unexplored component, which has been shown to play a role in 266 
people6, is cumulative (or absolute) glucocorticoid dose. Long-term, high-dose 267 
glucocorticoid (high cumulative dose) use has been associated with 268 
development of GIDM in people and that cessation or alternating-day therapy 269 
is protective (low cumulative dose)12. Cumulative dose calculation was not 270 
performed in this study due to lack of details in medical records regarding dose 271 
changes during the treatment period. No differences related to duration of 272 
therapy was found between PIDM and non-PIDH groups in our study. This, 273 
however, could be due to an inadequate study population or that we did not 274 
follow enough cases with prolonged prednisolone therapy. Two of the cats in 275 
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the PIDM group developed diabetes mellitus 108 and 128 weeks after initiation 276 
of prednisolone therapy. Both of these cats were diagnosed with immune-277 
mediated diseases and cessation of prednisolone was not achieved from 278 
initiation of prednisolone treatment to the development of diabetes. As such, 279 
both cats probably had a high cumulative dose. Prospective studies are needed 280 
in cats to assess the effects of prednisolone dose, cumulative dose and 281 
frequency of administration on PIDM development.    282 
Relative glucocorticoid potency has been shown to play a role in human GIDM, 283 
however prednisolone was chosen as the glucocorticoid of choice for this study 284 
as this was the most commonly used glucocorticoid during the study period in 285 
our hospital, only with a very few cases receiving long-term dexamethasone 286 
and methylprednisolone. One of the cats in the non-PIDM group, however, 287 
developed diabetes mellitus after cessation of prednisolone therapy, but 288 
following methylprednisolone injections treatment. This is consistent with 289 
previous experimental studies showing that methylprednisolone also is 290 
diabetogenic in cats10,15.  291 
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Interestingly, BCS was not significantly associated with development of PIDM, 292 
which is in contrast to what has been shown in cats with spontaneously 293 
occurring diabetes mellitus3 and from a pharmacological point of view, where it 294 
has been shown that overweight cats have higher plasma prednisolone levels 295 
than normal conditioned cats16. The lack of association noted in our study could 296 
be due to a lack of power in the study, compliance in reporting BCS in our 297 
medical records or perhaps due to weight loss prior to presentation secondary 298 
to the underlying diseases.  299 
Insulin therapy was only started in 9/14 cats, despite all cats fulfilling criteria 300 
for the diagnosis of diabetes mellitus. We were not able to clarify the clinical 301 
reasoning why five of the cats did not receive insulin, but in most cats the 302 
prednisolone dose was reduced at the time of DM diagnosis. We suspect that 303 
this was adequate to improve glycaemic control in some cats and therefore 304 
diminished the need for insulin treatment. Further studies are needed to 305 
determine optimal therapy for cats developing PIDM.  306 
Finally, none of the biochemical abnormalities typically associated with DM 307 
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were predictive of PIDM. This is likely due to the low number of cases of PIDM, 308 
however the finding of a trend towards an association between glucosuria 309 
present prior to therapy and development of PIDM is interesting. This could 310 
reflect impaired glucose tolerance and therefore could serve as a marker to 311 
identify cats being predisposed to development of PIDM, but further studies 312 
are needed to conclude on this matter. Based on this study it would be prudent 313 
to advise close monitoring of cats with glucosuria prior to prednisolone therapy 314 
for development of PIDM, especially during the first 3 months of therapy. As 315 
with any retrospective study, the lack of standardised treatment, follow-up and 316 
a significant number of cases and details lost to follow up, the conclusions of 317 
this study should be interpreted with caution.  318 
 319 
Conclusion 320 
Cats requiring high-dose prednisolone therapy should be closely monitored 321 
over the first 3 months of therapy for development of prednisolone-induced 322 
diabetes mellitus.  323 
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